GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

Home・Aandelen Lijst・BioArctic AB

B
BioArctic AB

Gesloten

284.6 -2.47

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

284.2

Max

285.2

Belangrijke statistieken
By Trading Economics
Inkomsten	-896M 179M
Verkoop	-897M 392M
K/W Sectorgemiddelde	23.701 35.69
EPS	1.09
Winstmarge	45.668
Werknemers	119
EBITDA	-893M 188M

Marktinformatie
By TradingEconomics
Marktkapitalisatie	4.5B 25B
Vorige openingsprijs	287.07
Vorige sluitingsprijs	284.6

BioArctic AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 sep 2025, 18:25 UTC

Belangrijke Marktbewegers

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27 sep 2025, 07:00 UTC

Winsten

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27 sep 2025, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

26 sep 2025, 21:56 UTC

Acquisities, Fusies, Overnames

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 sep 2025, 20:54 UTC

Winsten

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 sep 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

26 sep 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sep 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

26 sep 2025, 19:54 UTC

Marktinformatie

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 sep 2025, 19:53 UTC

Acquisities, Fusies, Overnames

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sep 2025, 19:40 UTC

Winsten

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 sep 2025, 19:24 UTC

Marktinformatie

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 sep 2025, 19:17 UTC

Marktinformatie

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 sep 2025, 19:15 UTC

Marktinformatie

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 sep 2025, 19:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

26 sep 2025, 19:03 UTC

Marktinformatie

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 sep 2025, 18:50 UTC

Marktinformatie

Winsten

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 sep 2025, 18:36 UTC

Marktinformatie

Silver Closes Out Week With Strong Surge -- Market Talk

26 sep 2025, 18:02 UTC

Acquisities, Fusies, Overnames

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 sep 2025, 18:02 UTC

Acquisities, Fusies, Overnames

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 sep 2025, 18:02 UTC

Acquisities, Fusies, Overnames

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 sep 2025, 17:54 UTC

Marktinformatie

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 sep 2025, 16:56 UTC

Marktinformatie

Winsten

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 sep 2025, 16:41 UTC

Marktinformatie

Winsten

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 sep 2025, 16:26 UTC

Winsten

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 sep 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

26 sep 2025, 16:12 UTC

Marktinformatie

Nike Stock Seen With Limited Upside -- Market Talk

26 sep 2025, 15:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

26 sep 2025, 15:59 UTC

Marktinformatie

Nike Seen Showing Progress in Turnaround -- Market Talk

Peer Vergelijking

Prijswijziging

BioArctic AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.